Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer

Journal: Cancer Research

Published: 2019-05-15

DOI: 10.1158/0008-5472.can-18-2812

Affiliations: 14

Authors: 17

Go to article
Institutions Share
Division of Hematology and Oncology, NU, United States of America (USA) 0.38
The Institute of Cancer Research (ICR), United Kingdom (UK) 0.15
The Royal Marsden Hospital - London, The Royal Marsden NHS Foundation Trust, United Kingdom (UK) 0.09
Robert H. Lurie Comprehensive Cancer Center, NU, United States of America (USA) 0.06
Human Biology Division, FHCRC, United States of America (USA) 0.06
Michigan Center for Translational Pathology (MCTP), U-M, United States of America (USA) 0.06
Department of Urology, UW, United States of America (USA) 0.06
Department of Pathology, NU, United States of America (USA) 0.03
UCLA Division of Hematology/Oncology, United States of America (USA) 0.03
VA Greater Los Angeles Healthcare System, United States of America (USA) 0.03
UCSF Department of Radiation Oncology, United States of America (USA) 0.01
UCSF Department of Urology, United States of America (USA) 0.01
UCSF Department of Medicine (DOM), United States of America (USA) 0.01
UCSF Helen Diller Family Comprehensive Cancer Center, United States of America (USA) 0.01

Return

Except where otherwise noted © 2019 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER